- Home
- CBAT vs BCAB Comparison
CBAT vs BCAB Comparison
Compare CBAT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBAT | BCAB |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBAT | BCAB |
|---|---|---|
| Price | $0.89 | $0.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 120.7K | ★ 2.1M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,757,685.00 | N/A |
| Revenue This Year | $16.06 | N/A |
| Revenue Next Year | $70.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $0.24 |
| 52 Week High | $1.28 | $1.72 |
Technical Indicators
Market Signals| Indicator | CBAT | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 48.78 |
| Support Level | $0.86 | $0.79 |
| Resistance Level | $0.91 | $0.90 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 43.42 | 14.41 |
Price Performance
Historical ComparisonAbout CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.